-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Cardiology
- Clinics
- Consumer Products
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Neurology
- OBGYN
- Oncology
- Ophthalmology
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Psychiatry
- Radiology
- Rheumatology
- Risk Manager
- Uncategorized
Category Archives: Endocrinology
Aliskiren containing Medications Drug Safety Comunication
Aliskiren-containing Medications: Drug Safety Comunication – New Warning and Contraindication including: Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide) Tekturna (aliskiren hemifumarate) Tekturna HCT (aliskiren hemifumarate and hydrochlorothiazide) Tekamlo (aliskiren hemifumarate and amlodipine besylate) Valturna (aliskiren hemifumarate and valsartan). Valturna will … Continue reading
Posted in Endocrinology, FDA 2012, FDA Safety Communication, Internal Medicine, Pharmacy
Tagged Aliskiren containing Medications, aliskiren hemifumarate, aliskiren hemifumarate and amlodipine besylate, aliskiren hemifumarate and hydrochlorothiazide, aliskiren hemifumarate and valsartan, amlodipine besylate, Amturnide, and hydrochlorothiazide, Drug Safety Communication, Endocrinology, fda, Internal Medicine, Pharmacy, Tekamlo, Tekturna, Tekturna HCT, Valturna
Comments Off
Is Avandia Worth The Risk?
Is Avandia Worth The Risk? There has been several reported deaths from Avandia from heart attacks and strokes but meanwhile the FDA has refused to recall it. they have only recently updated their warnings about the increased risks to patients. … Continue reading
Posted in Avandia, Endocrinology, FDA 2011, FDA Warning
Tagged adverse, Avandia, Avandia(rosiglitazone), benefits, diabetes, drug, drug risks, effects, fda, FDA warning, lawsuits, Risks, safety label changes, side effects and risk of Avandia, type 2
Comments Off
Reclast zoledronic acid
Reclast (zoledronic acid): Drug Safety Communication – New Contraindication and Updated Warning on Kidney Impairment AUDIENCE: Endocrinology, Pharmacy, Patient ISSUE: FDA notified healthcare professionals and patients of an update to the drug label for Reclast (zoledronic acid) regarding the risk … Continue reading
Posted in Endocrinology, FDA 2011, Pharmacy
Tagged Drug Safety Communication, Endocrinology, FDA notice, FDA warning, Patient, Pharmacy
Comments Off